Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value

British Journal of Cancer

Volumn 103, Issue 8, 2010, Pages 1201-1208

  Michlmayr, A ^a   Bachleitner Hofmann, T ^a   Baumann, S ^a   Marchetti Deschmann, M ^b   Rech Weichselbraun, I ^c   Burghuber, C ^a   Pluschnig, U ^a   Bartsch, R ^a   Graf, A ^a   Greil, R ^d   Allmaier, G ^b   Steger, G ^a   Gnant, M ^a   Bergmann, M ^a   Oehler, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^c Bender MedSystems   (Austria)

^d Private Medical University Salzburg   (Austria)

Author keywords

breast cancer; complement system; docetaxel; epirubicin; response to therapy

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ANTICHYMOTRYPSIN; CELL ADHESION MOLECULE; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOCETAXEL; EPIRUBICIN; FETUIN A; GRANULOCYTE COLONY STIMULATING FACTOR; INTER ALPHA TRYPSIN INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 6; PROTEOME; SOLUBLE INTRACELLULAR ADHESION MOLECULE 3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; COMPLEMENT; PHARMACOLOGICAL BIOMARKER; TAXOID; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; COMPLEMENT SYSTEM; FEMALE; GEL ELECTROPHORESIS; HUMAN; MASS SPECTROMETRY; MULTIPLE CYCLE TREATMENT; PLASMA; PRIORITY JOURNAL; TREATMENT RESPONSE; ADJUVANT THERAPY; BLOOD; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMISTRY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; VALIDATION STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMPLEMENT SYSTEM PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PLASMA; PREDICTIVE VALUE OF TESTS; TAXOIDS; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 77957999549     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605909     Document Type: Article

References (32)

1. Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R (2007) Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 178(9): 5991-5998
2. Apetoh L, Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Piacentini M, Kroemer G, Zitvogel L (2007) Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells. Cancer genomics & proteomics 4(2): 65-70
3. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Stat Soc B 57(1): 289-300
4. de Vries P, Singer JW (2000) Lisofylline suppresses ex vivo release by murine spleen cells of hematopoietic inhibitors induced by cancer chemotherapeutic agents. Exp hematol 28(8): 916-923
5. Debucquoy A, Haustermans K, Daemen A, Aydin S, Libbrecht L, Gevaert O, De Moor B, Tejpar S, McBride WH, Penninckx F, Scalliet P, Stroh C, Vlassak S, Sempoux C, Machiels JP (2009) Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 27(17): 2751-2757
6. Elsea CR, Roberts DA, Druker BJ, Wood LJ (2008) Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluoro-uracil, and doxorubicin without affecting tumoricidal activity. PloS one 3(6): e2355
7. Goncalves A, Esterni B, Bertucci F, Sauvan R, Chabannon C, Cubizolles M, Bardou VJ, Houvenaegel G, Jacquemier J, Granjeaud S, Meng XY, Fung ET, Birnbaum D, Maraninchi D, Viens P, Borg JP (2006) Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 25(7): 981-989
8. Gorter A, Meri S (1999) Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunology today 20(12): 576-582
9. Habermann JK, Roblick UJ, Luke BT, Prieto DA, Finlay WJ, Podust VN, Roman JM, Oevermann E, Schiedeck T, Homann N, Duchrow M, Conrads TP, Veenstra TD, Burt SK, Bruch HP, Auer G, Ried T (2006) Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 131(4): 1020-1029, quiz 1284
10. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18(12): 1927-1934
11. Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, Seregni E, Morelli D, Yu Y, Meng XY, Zhang Z, Davidson NE, Fung ET, Chan DW (2005) Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin chem 51(12): 2229-2235
12. Li K, Sacks SH, Zhou W (2007) The relative importance of local and systemic complement production in ischaemia, transplantation and other pathologies. Mol immunol 44(16): 3866-3874
13. Lin Y, Goedegebuure PS, Tan MC, Gross J, Malone JP, Feng S, Larson J, Phommaly C, Trinkaus K, Townsend RR, Linehan DC (2006) Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients. J Proteome Res 5(9): 2169-2176
14. Loveland BE, Cebon J (2008) Cancer exploiting complement: a clue or an exception? Nat Immunol 9(11): 1205-1206
15. Macor P, Tedesco F (2007) Complement as effector system in cancer immunotherapy. Immunol Lett 111(1): 6-13
16. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD (2008) Modulation of the antitumor immune response by complement. Nat Immunol 9(11): 1225-1235
17. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1): 207-214
18. Nakshatri H, Qi Q, You J, Kerry B, Schneider B, Zon R, Buck C, Regnier F, Wang M (2009) Intrinsic subtype-associated changes in the plasma proteome in breast cancer. Proteomics Clin Appl 3: 1305-1313
19. Paidassi H, Tacnet-Delorme P, Garlatti V, Darnault C, Ghebrehiwet B, Gaboriaud C, Arlaud GJ, Frachet P (2008) C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J Immunol 180(4): 2329-2338
20. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27): 2817-2826
21. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20(18): 3551-3567
22. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR (2006) Genomic signatures to guide the use of chemotherapeutics. Nat Med 12(11): 1294-1300
23. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, Slack R, Hayes DF (2003) A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 9(1): 124-133
24. Stift A, Prager G, Selzer E, Widder J, Kandioler D, Friedl J, Teleky B, Herbst F, Wrba F, Bergmann M (2003) The early response of p53-dependent proteins during radiotherapy in human rectal carcinoma and in adjacent normal tissue. Int J Oncol 23(5): 1269-1275
25. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347(25): 1999-2009 (Pubitemid 35461656)
26. Vandivier RW, Ogden CA, Fadok VA, Hoffmann PR, Brown KK, Botto M, Walport MJ, Fisher JH, Henson PM, Greene KE (2002) Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol 169(7): 3978-3986
27. Vorm O, Roepstorff P, Mann M (1994) Improved resolution and very high sensitivity in MALDI TOF of matrix surfaces made by fast evaporation. Anal Chem 66(19): 3281-3287
28. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A (2006) Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 94(12): 1898-1905
29. Winkler W, Zellner M, Diestinger M, Babeluk R, Marchetti M, Goll A, Zehetmayer S, Bauer P, Rappold E, Miller I, Roth E, Allmaier G, Oehler R (2008) Biological variation of the platelet proteome in the elderly population and its implication for biomarker research. Mol Cell Proteomics 7(1): 193-203
30. Zellner M, Winkler W, Hayden H, Diestinger M, Eliasen M, Gesslbauer B, Miller I, Chang M, Kungl A, Roth E, Oehler R (2005) Quantitative validation of different protein precipitation methods in proteome analysis of blood platelets. Electrophoresis 26(12): 2481-2489
31. Zhang W, Chait BT (2000) ProFound: an expert system for protein identification using mass spectrometric peptide mapping information. Anal Chem 72(11): 2482-2489
32. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev 8(1): 59-73